{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:11:53Z","timestamp":1784776313166,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007028","name":"The Leona M and Harry B Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024250","name":"Israel Innovation Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tibtech.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:41:17Z","timestamp":1778013677000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Detection of anti-drug antibodies during monoclonal antibody drug therapy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5123-1771","authenticated-orcid":false,"given":"Frans","family":"Kokojka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-7513","authenticated-orcid":false,"given":"Denis","family":"Mulleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9697-3805","authenticated-orcid":false,"given":"Robert S.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.04.003_bb0005","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1038\/s41598-024-53554-7","article-title":"Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980\u20132022","volume":"14","author":"Seoane-Vazquez","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0010","first-page":"280","article-title":"The emergence of antibodyplus: the future trend of antibody-based therapeutics","volume":"5","author":"Zhu","year":"2022","journal-title":"Antib. Ther."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0015","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cpt.3573","article-title":"IQ survey results on current industry practices: part 2\u2014quantitative evaluations of immunogenicity assessment","volume":"117","author":"Richards","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fimmu.2015.00109","article-title":"Immunogenicity of anti-TNF-alpha biotherapies: II. Clinical relevance of methods used for anti-drug antibody detection","volume":"6","author":"Bendtzen","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0035","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0040","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1208\/s12248-015-9857-y","article-title":"Evaluating and reporting the immunogenicity impacts for biological products \u2013 a clinical pharmacology perspective","volume":"18","author":"Wang","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0045","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/01.wnl.0000258545.73854.cf","article-title":"Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"68","author":"Goodin","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0050","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1208\/s12248-016-9954-6","article-title":"Strategies to determine assay format for the assessment of neutralizing antibody responses to biotherapeutics","volume":"18","author":"Wu","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0055","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/MIB.0000000000000797","article-title":"Anti-infliximab antibodies with neutralizing capacity in patients with inflammatory bowel disease: distinct clinical implications revealed by a novel assay","volume":"22","author":"Weisshof","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100004","article-title":"Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: infliximab as proof of principle","volume":"1","author":"El Amrani","year":"2019","journal-title":"J. Transl. Autoimmun."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1429544","article-title":"Dynamics and implications of anti-drug antibodies against adalimumab using ultra-sensitive and highly drug-tolerant assays","volume":"15","author":"Ding","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","article-title":"The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region","volume":"74","author":"van Schie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0075","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaci.2016.09.014","article-title":"Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: the immune response to antibody therapeutics preferentially targets the antigen-binding site","volume":"139","author":"van Schie","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0080","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/annrheumdis-2018-213299","article-title":"Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies","volume":"77","author":"van Schie","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0085","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2665-9913(23)00341-7","article-title":"Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials","volume":"6","author":"Brun","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","article-title":"Immunogenicity of biologic agents in rheumatology","volume":"17","author":"Strand","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155627","article-title":"Immunogenicity of monoclonal antibody: causes, consequences, and control strategies","volume":"263","author":"Asmani","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0100","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/rheumatology\/kead690","article-title":"Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases","volume":"64","author":"Martinez-Feito","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0105","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/apt.16333","article-title":"Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease","volume":"53","author":"Tournier","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0110","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fimmu.2020.01365","article-title":"Drug tolerant anti-drug antibody assay for infliximab treatment in clinical practice identifies positive cases earlier","volume":"11","author":"Kharlamova","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0115","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/jssc.202200112","article-title":"Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: a review","volume":"45","author":"Suh","year":"2022","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bcpt.13983","article-title":"Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: a snapshot of laboratories and applications across Europe","volume":"134","author":"Skrede","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","volume":"2016","author":"Song","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/cei.13112","article-title":"Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab","volume":"192","author":"Gorovits","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0135","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0004563218782286","article-title":"Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases","volume":"56","author":"Sanchez-Hernandez","year":"2019","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0145","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/BOR.0000000000000713","article-title":"Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology","volume":"32","author":"Papamichael","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0150","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tibtech.2025.07.003","article-title":"Challenges in realizing therapeutic antibody biosensing","volume":"44","author":"Nagata","year":"2025","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0160","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.tibtech.2020.03.001","article-title":"On-site therapeutic drug monitoring","volume":"38","author":"Ates","year":"2020","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0165","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0000000000001095","article-title":"Challenges in therapeutic drug monitoring: optimizing biological treatments in patients with inflammatory bowel disease and other immune-mediated inflammatory diseases","volume":"45","author":"Papamichael","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.112842","article-title":"Anti-infliximab antibodies: how to compare old and new data?","volume":"177","author":"Imbrechts","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94431-x","article-title":"Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients\u2019 sera","volume":"11","author":"Beeg","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0180","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0000000000000404","article-title":"Immunogenicity of therapeutic antibodies: monitoring antidrug antibodies in a clinical context","volume":"39","author":"Bloem","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0185","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/apt.16135","article-title":"Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays","volume":"53","author":"Nice","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12348-025-00520-7","article-title":"Characteristics of patients who developed transient anti-adalimumab antibodies","volume":"15","author":"Elaraby","year":"2025","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1401178","article-title":"What are clinically significant anti-drug antibodies and why is it important to identify them","volume":"15","author":"Swanson","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0205","doi-asserted-by":"crossref","first-page":"S018","DOI":"10.1093\/ecco-jcc\/jjz203.020","article-title":"OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service","volume":"14","author":"Nice","year":"2020","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40259-022-00559-1","article-title":"Assessing immunogenicity of biologic drugs in inflammatory joint diseases: progress towards personalized medicine","volume":"36","author":"Gehin","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0215","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0220","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/flgastro-2016-100692","article-title":"Assays for measurement of TNF antagonists in practice","volume":"8","author":"Vande Casteele","year":"2017","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820965790","article-title":"Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays","volume":"13","author":"Rocha","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154859","article-title":"Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: a comparison of three commercially available ELISA kits","volume":"126","author":"Bertin","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u02ca)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0240","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0245","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3389\/fimmu.2019.02921","article-title":"Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFalpha antagonists","volume":"10","author":"Vaisman-Mentesh","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0250","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jim.2015.08.002","article-title":"A breakthrough novel method to resolve the drug and target interference problem in immunogenicity assays","volume":"426","author":"Zoghbi","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0255","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/s12248-022-00759-1","article-title":"Determination of anti-drug antibody affinity in clinical study samples provides a tool for evaluation of immune response maturation","volume":"24","author":"Joyce","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21858","article-title":"Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels","volume":"9","author":"Xiang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/FTD.0000000000001200","article-title":"Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection in the clinical laboratory","volume":"46","author":"Keating","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112672","article-title":"Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum","volume":"474","author":"Hock","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0275","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0280","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0285","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1208\/s12248-020-0431-x","article-title":"Development of a cell-based assay for the detection of neutralizing antibodies to PF-06730512 using homogenous time-resolved fluorescence","volume":"22","author":"Luong","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0290","doi-asserted-by":"crossref","first-page":"14273","DOI":"10.1021\/acs.analchem.5c01017","article-title":"Rapid and wash-free anti-drug antibody assay enabled by a complementary nanoluciferase biosensor","volume":"97","author":"Sun","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0295","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41598-018-37950-4","article-title":"A surface plasmon resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies","volume":"9","author":"Beeg","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0300","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/clinchem\/hvaa179","article-title":"Development of label-free immunoassays as novel solutions for the measurement of monoclonal antibody drugs and antidrug antibodies","volume":"66","author":"Luo","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0305","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1007\/s00216-017-0674-2","article-title":"Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics","volume":"409","author":"Dubiel","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0310","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1039\/D0CC03399E","article-title":"Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors","volume":"57","author":"Sensi","year":"2021","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211352","article-title":"Reduced graphene oxide electrolyte-gated transistor immunosensor with highly selective multiparametric detection of anti-drug antibodies","volume":"35","author":"Sensi","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202505975","article-title":"Drug-tolerant, chemiluminescent lateral flow immunoassay platform for the determination of neutralizing anti-drug antibodies","volume":"21","author":"Kokojka","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95055-x","article-title":"Sensitive assay design for detection of anti-drug antibodies to biotherapeutics that lack an immunoglobulin Fc domain","volume":"11","author":"Johnson","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0330","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0335","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68050-x","article-title":"A portable optical-fibre-based surface plasmon resonance biosensor for the detection of therapeutic antibodies in human serum","volume":"10","author":"Zeni","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.04.003_bb0345","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/trf.17818","article-title":"A portable surface plasmon resonance (SPR) sensor for the detection of immunoglobulin A in plasma","volume":"64","author":"Dubois","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tibtech.2026.04.003_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2024.127240","article-title":"Rapid and specific screening of monoclonal antibodies in hybridoma supernatants by an enzyme-based dipstick immunoassay","volume":"284","author":"Kokojka","year":"2025","journal-title":"Talanta"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926001381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926001381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:15:51Z","timestamp":1778732151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926001381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":70,"alternative-id":["S0167779926001381"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.04.003","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of anti-drug antibodies during monoclonal antibody drug therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}